Those Who Suffer Much, Know Much 2010 - User Control Panel

Linda’s been an active LDN advocate for many years and is fully supported byher trust directors Dr Bob Lawrence, Dr Tom Gilhooly, and a band of Trustvolunteers who, like Linda, volunteer their time in the interest of raisingawareness of LDN so others might benefit. The good doctors are not just Trustdirectors, they have successfully treated patients with LDN and havecontributed significantly to enhancing awareness of LDN across Europe, withUK television personality, Dr Chris Steele of IT ‘This Morning’ learning firsthandof LDN from Dr Tom Gilhooly.LDN Now, formed in 2009 by Jayne Crocker and Andrew Barnett, is anadvocacy group focused on petitioning governments to review LDN as atreatment option. To-date the group has submitted petitions and leveraged thevideotaped support of Dr Chris Steele. Of particular note is a videotapedScottish parliamentary committee meeting in 2009 during which discussionabout their LDN petition was led by Scottish LDN advocates, Bob, Celia, andMargaret (you’ll find this video link within ‘Advocate’ pages).The ‘LDN story’ is an international phenomenon; a worldwide advocatemovement of all those who know of LDN and all those patients who’vebenefited from LDN. Everyone is doing everything they can to raise awarenessand promote further research and clinical trials… the hard way.You can’t help but be impressed when you see sufferers of a range of diseasesraising funds and volunteering their time in support groups, in spite of theirown daily health challenges - all in the interest of helping other sufferers learnof and benefit from LDN as they have.And this collective advocacy effort has achieved outstanding progress: A 2009advocate survey of known compounding pharmacies worldwide prompted MaryBoyle Bradley (angel of the LDN airwaves) to announce at the 2009 USAconference that an estimated 100,000 patients are now taking LDNinternationally.Skip Lenz of Skip’s Pharmacy (Florida, USA) is now compounding tens ofthousands of 3-month LDN prescriptions every month. Further, Skip’s desire tocontribute to the evidence base for LDN efficacy prompted him years ago toinitiate his first MS patient population survey, and his latest results continue toconfirm a consistently high favourable response rate:At the 2009 USA Conference, Skip Lenz of Skips Pharmacy in Floridareported 83% of his pharmacy’s LDN/MS patient population had nothad a relapse in over 3 years.Clearly, if LDN was a new, patented, high cost, profit-generatingdrug or vaccine, it would have won it’s early discoverers or clinicaladopter the Nobel Prize long ago.Please pause to fully absorb what you’ve read so far and what all this means: Case Health Pty LtdRevised – July 2007, July 2008, July 2009, July 2010Page 18/433